“At Gateway Natural Medicine, I believe healthcare should be personal, root-cause focused, and natural. Too often, patients are given quick fixes that overlook the underlying issue — my mission is to change that. If you’re seeking a natural, patient-centered approach to healthcare that focuses on long-term healing rather than temporary relief — you’ve come to the right place. Let’s begin your journey toward balance, restoration, and lasting health.”
Most people are familiar with the basic annual report card for heart health: the standard lipid panel. This usually gives you a snapshot of Total Cholesterol, HDL, Triglycerides, and Non-HDL Cholesterol (which is essentially everything that isn’t HDL, including LDL, VLDL, IDL, and Lp(a)).
However, looking at this basic panel is a bit like judging a book solely by its page count. It tells you something, but it misses the plot. This article explores atherosclerosis risk assessment using advanced blood chemistry markers that go beyond the limitations of the traditional lipid panel. This is especially true when it comes to LDL, which is rarely measured directly in standard labs. Instead, it’s calculated using math that feels a bit outdated.
Table of Contents
The Math Behind the Medicine
Historically, labs used the Friedewald equation:
LDL = Total Cholesterol – HDL – (Triglycerides / 5)
Then, researchers realized this wasn’t quite right for everyone, so they introduced newer calculations. One is better for people with high triglycerides:
LDL = Total Cholesterol – HDL – (Triglycerides / 8.59)
And then there is the Martin/Hopkins or Sampson calculation, which is theoretically more accurate for low LDL but looks like something written by a physicist having a bad day:
LDL = Total Cholesterol/0.948 – HDL/0.971 – (Triglycerides/8.56 + Triglycerides x Non-HDL Cholesterol/2104 – Triglycerides squared/16100) – 9.44
If your eyes glazed over reading that, I don’t blame you. I’m sorry for the seconds of your life you won’t get back.
Why Do We Rely on Math Instead of Measurement?
Here is the precedent: The medical system calculates LDL rather than measuring it directly primarily because of convenience and cost. Direct measurement exists, and it is more accurate, but it costs more.
Essentially, the standard of care often settles for “good enough” testing to reach a very specific conclusion: that you need a cholesterol-lowering medication, usually a statin.
While statins have their place, the “treat to the calculated number” approach ignores the reality of side effects. These can range from brain fog and fatigue to myalgias (muscle aches). And remember, the heart is a muscle—so “muscle aches” are not something to take lightly when discussing cardiovascular health. Other potential issues include decreased libido, rising blood sugar (increasing diabetes risk), and rarely, rhabdomyolysis (a severe, toxic muscle breakdown).
If we want to avoid the medication-go-round and truly understand your risk, we need better data.
Going Deeper: Understanding Advanced Testing
Let’s move past the basics and look at diagnostics that actually tell us about the health of your arteries and the progression of atherosclerosis (plaque buildup).
Lipid NMR (Nuclear Magnetic Resonance)
Think of the standard lipid panel as telling you the weight of traffic on a highway. A Lipid NMR tells you exactly what kind of cars are on the road.
This test measures the number and size of particles: HDL, LDL, and VLDL.
- Large HDL: These are the heroes. They are cardiovascular protective because they perform reverse cholesterol transport. They grab fat deposits from the bloodstream and ship them to the liver to be processed and eliminated (mostly via stool).
- Large VLDL: These are the troublemakers. They are associated with metabolic issues (high blood pressure, high sugar) and are prone to depositing fat into the bloodstream.
- Small LDL vs. Large LDL: This is the most critical distinction.
The Gumball Analogy
Imagine a gumball machine that only accepts pennies. You have a pocket full of change: quarters and pennies.
- Large LDL particles are like quarters. They are too big to slip into the “slot” of the artery wall.
- Small LDL particles are like pennies. They slip right through the arterial lining (the intima) and start the inflammatory process that leads to clogging.
A standard lab might tell you that you have an LDL of 100. But having 100 pennies (small, dense, artery-clogging particles) is vastly more dangerous than having 4 quarters (large, fluffy, harmless particles). Without an NMR, you are just guessing.
The Fire Inside: Inflammation & Oxidative Damage
Even if you know your particle size, you need to know if your arteries are inflamed. Here is the trio of markers that helps us see the “fire” inside the vessel.
Oxidized LDL (The “Rancid” Cholesterol)
What happens when milk sits out too long? It spoils. Oxidized LDL is essentially LDL cholesterol that has gone rancid after interacting with Reactive Oxygen Species (ROS).
When LDL becomes oxidized, the body’s immune system stops recognizing it as normal cholesterol and treats it like an invader. This triggers the creation of foam cells, which are the building blocks of plaque.
Note: We measure serum oxidized LDL (what’s floating in your blood), but the real damage happens when this LDL gets into the artery wall. High levels usually signal systemic inflammation caused by smoking, high sugar intake, insulin resistance, or a sedentary lifestyle. The fix? Antioxidants (eat your colorful veggies!) and lifestyle changes.
Myeloperoxidase (MPO)
If Oxidized LDL is the spark, MPO is the accelerant.
MPO is an enzyme released by white blood cells after the Oxidized LDL has burrowed into the artery wall. It is not usually found floating freely in the blood. If we find it there, it suggests the arterial walls are under attack. MPO interacts directly with the plaque, making it unstable and increasing the risk of it bursting.
Lp-PLA2 (The “Placard” of Instability)
Lp-PLA2 is an enzyme that tries to clean up the mess. Once Oxidized LDL is in the artery wall, the body sends Lp-PLA2 to break it down (hydrolysis).
Unfortunately, this cleanup process produces irritating chemicals that further inflame the artery. High levels of Lp-PLA2 indicate that your plaque is fragile. If plaque ruptures, it blocks blood flow, leading to a heart attack or stroke. Think of this marker as a specific gauge for “plaque instability.”
The Logistics Crew: Apo-A1 and Apo-B
To simplify the transport system of cholesterol, we look at Apolipoproteins.
- Apo-B (The Garbage Trucks): This protein is attached to every “bad” particle (LDL, VLDL, IDL). It carries the cholesterol that can end up as trash on the street (plaque in the arteries).
- Apo-A1 (The Street Sweepers): This protein is attached to HDL. Its job is to clean up the mess.
If you have a fleet of garbage trucks (High Apo-B) leaking trash everywhere, and only one street sweeper (Low Apo-A1), you are going to get pile-ups.
Optimal Target: You want an Apo-B to Apo-A1 ratio of less than 0.6. Anything higher signals increased risk.
The Genetic Wildcard: Lipoprotein(a)
Finally, we have Lipoprotein little a, or Lp(a).
This is primarily a genetic marker. It is arguably the most dangerous lipid because it is a triple threat:
- It carries Apo-B, so it promotes plaque like LDL.
- It is highly prone to oxidation, causing more inflammation.
- It promotes clotting. The structure of Lp(a) mimics a protein involved in dissolving clots. By tricking the body, it prevents clots from breaking down.
Because it is genetic, diet and exercise have a limited impact on Lp(a) levels, but knowing you have it changes how aggressively we manage every other risk factor.
Summary: The “Real” Heart Health Panel
If you want a true representation of your cardiovascular health, look beyond the basic lipid panel. Ask for:
Lp(a) (to check your genetic risk)
Lipid NMR (to see particle size)
Oxidized LDL (to check for “rancid” cholesterol)
Myeloperoxidase (MPO) (to check for arterial wall stress)
Lp-PLA2 (to check for plaque instability)
Apo-B and Apo-A1 (to check the ratio of delivery vs. cleanup)
References
- Keys A. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Harvard University Press; 1980.
- Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390(10107):2050-2062.
- Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010;91(3):502-509.
- Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21(4):305-311.
- Mozaffarian D, Ludwig DS. The 1977 Dietary Goals and their unintended consequences. JAMA. 2015;313(5):463-464.
- Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond ‘calories in, calories out’. JAMA Intern Med. 2018;178(8):1098-1103.
